SEC Form 4 · accession 0001601830-26-000083
RECURSION PHARMACEUTICALS, INC. · RXRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dean Y Li
Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 22, 2026 · 4:32 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001601830
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF2 | Jun 17, 2026 | A | 88,424 | $0.00 | A | 1,469,582 | D | |
| Class A Common Stock | holding | — | — | — | 1,422,048 | I | By Dean Y. Li Revocable Trust | |
| Class A Common Stock | holding | — | — | — | 421,000 | I | By Dean Y. Li 2021 Family Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
- F2Includes 136,981 shares of Class A common stock transferred from the Dean Y. Li GRAT on May 7, 2026.